Targeted Therapies in Melanoma

被引：8

作者：

Moschos, Stergios J. ^{[1
]}

Pinnamaneni, Ramya ^{[2
]}

机构：

[1] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA

[2] E Carolina Univ, Dept Med, Div Hematol Oncol, Greenville, NC 27834 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2015年 / 24卷 / 02期

关键词：

Melanoma; Next generation sequencing; BRAF inhibitors; Ocular melanoma; Immunotherapies; MUTATION-POSITIVE MELANOMA; STAGE-IV MELANOMA; MEK INHIBITION; OPEN-LABEL; BRAF INHIBITION; METASTATIC MELANOMA; ANTITUMOR-ACTIVITY; PROGRESSION-FREE; VEMURAFENIB; SURVIVAL;

D O I：

10.1016/j.soc.2014.12.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advances in the biology of melanoma have provided insights about chemoresistance and its genetic heterogeneity in parallel with advances in drug design, culminating in recent major treatment breakthroughs. Although clinical benefit of targeted therapies has been unquestionable, future advances are only possible if we understand the interplay between genetic aberrations and role of other crucial nongenetic changes yet to be identified by such projects as the Cancer Genome Atlas Project in Melanoma. Combination therapies, either among small molecule inhibitors themselves and/or with immunotherapies, may be the optimal strategy to prevent development of drug resistance inherently linked with such targeted therapies.

引用

页码：347 / +

页数：13

共 59 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2]

Algazi AP, 2014, ASCO ANN M MAY 30 JU

[3]

Angus SP, 2014, AACR ANN M APR 5 9 S

[4] Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort [J].

Ascierto, Paolo A. ;

Simeone, Ester ;

Sileni, Vanna Chiarion ;

Pigozzo, Jacopo ;

Maio, Michele ;

Altomonte, Maresa ;

Del Vecchio, Michele ;

Di Guardo, Lorenza ;

Marchetti, Paolo ;

Ridolfi, Ruggero ;

Cognetti, Francesco ;

Testori, Alessandro ;

Bernengo, Maria Grazia ;

Guida, Michele ;

Marconcini, Riccardo ;

Mandala, Mario ;

Cimminiello, Carolina ;

Rinaldi, Gaetana ;

Aglietta, Massimo ;

Queirolo, Paola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[5] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[6] Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function [J].

Boni, Andrea ;

Cogdill, Alexandria P. ;

Dang, Ping ;

Udayakumar, Durga ;

Njauw, Ching-Ni Jenny ;

Sloss, Callum M. ;

Ferrone, Cristina R. ;

Flaherty, Keith T. ;

Lawrence, Donald P. ;

Fisher, David E. ;

Tsao, Hensin ;

Wargo, Jennifer A. .

CANCER RESEARCH, 2010, 70 (13) :5213-5219

[7] Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial [J].

Carvajal, Richard D. ;

Sosman, Jeffrey A. ;

Quevedo, Jorge Fernando ;

Milhem, Mohammed M. ;

Joshua, Anthony M. ;

Kudchadkar, Ragini R. ;

Linette, Gerald P. ;

Gajewski, Thomas F. ;

Lutzky, Jose ;

Lawson, David H. ;

Lao, Christopher D. ;

Flynn, Patrick J. ;

Albertini, Mark R. ;

Sato, Takami ;

Lewis, Karl ;

Doyle, Austin ;

Ancell, Kristin ;

Panageas, Katherine S. ;

Bluth, Mark ;

Hedvat, Cyrus ;

Erinjeri, Joseph ;

Ambrosini, Grazia ;

Marr, Brian ;

Abramson, David H. ;

Dickson, Mark Andrew ;

Wolchok, Jedd D. ;

Chapman, Paul B. ;

Schwartz, Gary K. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23) :2397-2405

[8] The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].

Cerami, Ethan ;

Gao, Jianjiong ;

Dogrusoz, Ugur ;

Gross, Benjamin E. ;

Sumer, Selcuk Onur ;

Aksoy, Buelent Arman ;

Jacobsen, Anders ;

Byrne, Caitlin J. ;

Heuer, Michael L. ;

Larsson, Erik ;

Antipin, Yevgeniy ;

Reva, Boris ;

Goldberg, Arthur P. ;

Sander, Chris ;

Schultz, Nikolaus .

CANCER DISCOVERY, 2012, 2 (05) :401-404

[9] The Nature and Management of Metastatic Melanoma After Progression on BRAF Inhibitors: Effects of Extended BRAF Inhibition [J].

Chan, Matthew M. K. ;

Haydu, Lauren E. ;

Menzies, Alexander M. ;

Azer, Mary W. F. ;

Klein, Oliver ;

Lyle, Megan ;

Clements, Arthur ;

Guminski, Alexander ;

Kefford, Richard F. ;

Long, Georgina V. .

CANCER, 2014, 120 (20) :3142-3153

[10] BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma [J].

Colombino, Maria ;

Capone, Mariaelena ;

Lissia, Amelia ;

Cossu, Antonio ;

Rubino, Corrado ;

De Giorgi, Vincenzo ;

Massi, Daniela ;

Fonsatti, Ester ;

Staibano, Stefania ;

Nappi, Oscar ;

Pagani, Elena ;

Casula, Milena ;

Manca, Antonella ;

Sini, MariaCristina ;

Franco, Renato ;

Botti, Gerardo ;

Caraco, Corrado ;

Mozzillo, Nicola ;

Ascierto, Paolo A. ;

Palmieri, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2522-2529

← 1 2 3 4 5 6 →